Endocrinology Network: DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs

July 5, 2021

A review of data obtained from within the DISCOVER registry is offering clinicians insight into the prevalence of GLP-1 receptor agonists and SGLT2 inhibitors.

Presented at American Diabetes Association's 81st Scientific Sessions, information from the registry describes a slow, but gradual uptake in SGLT2 inhibitors but also outlines gaps in prescribing that leave many patients who could benefit the most without these medications.

Endocrinology Network talked to Dr. Suzanne Arnold, cardiologist at Saint Luke's Mid America Heart Institute, about the DISCOVER registry and the take-home message of its findings.

Read the full Endocrinology Network article: DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs

Related Content

Healio: DARE-19: Dapagliflozin well-tolerated for inpatient COVID-19 with, without diabetes
The SGLT2 inhibitor dapagliflozin is well-tolerated in adults hospitalized with COVID-19, regardless of diabetes status, according to new analyses from the DARE-19 trial.
Healio: No difference in sustained health status improvements in TAVR vs. surgical AVR
Patients who had TAVR had similar health status after five years with those who had surgical AVR, according to a new study by Dr. Suzanne Arnold.
Plaque in artery illustration
Cardiovascular Business: Patients with type 2 diabetes and heart disease may require more aggressive, modern treatments
Treating coronary artery disease in patients with type 2 diabetes may require a more aggressive treatment approach than normal, according to a new scientific statement from the AHA. Cardiovascular Business highlights the findings of Dr. Suzanne Arnold and her colleagues.